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REAKSI ADVERS DRUG DI KALANGAN PESAKIT DIMASUKKAN KE 
HOSPITAL DENGAN PENYAKIT BUAH PINGGANG KRONIK DI HOSPITAL 
DUBAI: RUJUKAN PADA KEUPAYAAN PENDARAHAN DI DALAM 
KALANGAN PESAKIT
ABSTRAK 
 Penyakit buah pinggang kronik (CKD) terdedah kepada Kesan Advers drug 
(ADR) kerana mereka biasanya berada dalam regimen pelbagai drug, mempunyai 
kriteria co-morbid yang berbeza, dan kerana perubahan dalam parameter farmakokinetik 
dan farmakodinamik. Matlamat keseluruhan tesis ini adalah untuk menilai kesan advers 
drug dalam kalangan pesakit  dimasukkan ke hospital dengan tahap yang sederhana ke 
CKD yang teruk, dan membangunkan skor risiko ADR untuk mengenal pasti dan 
mengklasifikasi pesakit CKD yang mempunyai risiko peningkatan ADR semasa di 
dalam hospital.
Untuk memenuhi objektif tesis, satu kajian secara pemerhatian telah dijalankan di 
unit buah pinggang Hospital Dubai, Emiriyah Arab Bersatu. Pesakit dengan peringkat 
CKD 3 hingga 5 (dianggarkan GFR, 10-59 ml/min/1.73 m2) yang dimasukkan ke unit 
buah pinggang, antara 1 Januari, 2012, dan 31 Disember, 2012 telah diambil. Bagi setiap 
pesakit, data dikumpulkan pada kemasukan dengan menggunakan borang yang seragam. 
Skor risiko ADR telah dibangunkan dengan membina satu siri model regresi logistik. 
Model patut keseluruhan dan model berjujukan telah dibandingkan dengan 
menggunakan Kriteria Maklumat Akaike. Nisbah ganjil pembolehubah disimpan dalam 
model terbaik yang digunakan untuk mengira skor risiko. Tambahan pula, analisis skor 
kecenderungan telah dijalankan untuk mengkaji hubungan penggunaan antikoagulan 
dengan hasil yang buruk, dan untuk menguji kesan perlindungan statin terhadap acara-
acara utama pendarahan yang disebabkan oleh terapi antikoagulasi.
xvi
Antara pesakit  dimasukkan ke hospital dengan CKD, sekurang-kurangnya 1 dalam 
8 pesakit mengalami ADR semasa penginapan hospital; pesakit CKD yang tidak berada 
di mana-mana terapi penggantian buah pinggang berada pada risiko yang lebih tinggi 
untuk mendapatkan ADR; dan, lebih separuh daripada jumlah ADR yang berkaitan 
dengan pendarahan adalah berkaitan dengan penggunaan antikoagulasi. Pendarahan 
besar berlaku pada 1 daripada 3 pesakit yang menerima terapi antikoagulasi semasa di 
hospital, dan pengguna antikoagulan adalah 3 kali lebih berkemungkinan untuk mati 
berbanding dengan mereka yang tidak menerima terapi antikoagulasi; walau 
bagaimanapun, statin mempunyai kaitan perlindungan dengan risiko pendarahan 
antikoagulan berkaitan.
Antara pesakit dimasukkan ke hospital dengan CKD, terdapat kepelbagaian besar 
dalam risiko untuk ADR. Dengan menggunakan skor risiko ADR, pesakit berisiko tinggi 
boleh menerima campur tangan yang lebih intensif yang bertujuan untuk mengurangkan 
hasil buruk berkaitan dadah dan meningkatkan keberkesanan kos terapi CKD. Dengan 
menggunakan skor ini juga, tahap risiko yang berbeza boleh digunakan untuk pesakit 
triage untuk keputusan mengenai permulaan terapi penggantian renal. Terapi 
antikoagulasi pada pesakit dimasukkan ke hospital dengan CKD nyata dikaitkan dengan 
peningkatan risiko pendarahan dan kematian utama di hospital. Risiko yang lebih tinggi 
diperhatikan dalam pelbagai kumpulan pesakit dan tidak berkurangan selepas pelarasan 
bagi faktor lain yang biasa. Keputusan ini menunjukkan bahawa langkah-langkah 
pencegahan seterusnya untuk mengurangkan bilangan kematian yang disebabkan oleh 
antikoagulan diperlukan.
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ADVERSE DRUG REACTIONS AMONG HOSPITALISED PATIENTS WITH 
CHRONIC KIDNEY DISEASE IN DUBAI HOSPITAL: WITH REFERENCE TO 
BLEEDING TENDENCY AMONG HOSPITALISED PATIENTS
ABSTRACT
Chronic kidney disease (CKD) patients are particularly vulnerable to adverse drug 
reaction (ADR) because they usually are on multiple drug regimens, have different 
comorbid conditions, and because of alteration in their pharmacokinetics and 
pharmacodynamic parameters. The overall aim of this thesis was to evaluate and assess 
adverse drug reactions among hospitalized patients with moderate to severe CKD, and to 
develop an ADR risk score to identify and stratify CKD patients who are at increased 
risk of ADRs during hospital stay. 
 To meet the objective of the thesis, a one year observational prospective study  
was conducted at the renal unit of Dubai Hospital, the United Arab Emirates. 
Consecutive patients with CKD stages 3 to 5 (estimated GFR, 10-59 ml/min/1.73 m2) 
who were admitted to the renal unit, between January 1, 2012, and December 31, 2012 
were recruited. For each patient, data was collected at admission using a standardized 
form. An ADR risk score was developed by constructing a series of logistic regression 
models. The overall model fit  for sequential models was compared using the Akaike 
Information Criterion. Odd ratios of the variables retained in the best model were used to 
compute the risk scores. Furthermore, a propensity  score analysis was undertaken to 
examine the relation of anticoagulant use with adverse outcomes, and to test the 
xviii
protective effects of statin on the major bleeding events caused by  anticoagulation 
therapy.
 Among hospitalised patients with CKD, at least 1 in 8 patients experienced an 
ADR during hospital stay; patients in ESRD who were not on any  renal replacement 
therapy were at higher risk of developing an ADR; and, more than half of the total ADRs 
were bleeding events related to anticoagulants use. Major bleeding occurred in 1 of 3 
patients who received anticoagulation therapy during hospital stay, and anticoagulant 
users were 3-times more likely to die when compared with those with no anticoagulation 
therapy; however, statin had a protective association with the anticoagulant-related 
bleeding events.
 Among hospitalised patients with CKD, there can be considerable heterogeneity  
in the risk for ADRs. By using the ADR risk score, higher-risk patients could receive 
more intensive interventions aimed at reducing the drug-related adverse outcomes and 
improving the cost-effectiveness of CKD therapy. Also, using this score, different risk 
levels could be used to triage patients for decision regarding the initiation of renal 
replacement therapy. Anticoagulation therapy in hospitalised patients with CKD was 
significantly associated with an increased risk of major bleeding and in-hospital 
mortality. Higher risk was observed in a range of patient groups and was not reduced 
after adjusting for the common cofounders. These results suggest that further preventive 
measures to reduce the number of death caused by anticoagulant is warranted. 
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CHAPTER 1
GENERAL INTRODUCTION
1
1.1 Prevalence of Chronic Kidney Disease
 Chronic kidney disease (CKD) is a major health problem worldwide, with a 
rising trend in prevalence and incidence, both in developed and developing countries. 
In the United States, the most recent  analysis from National Health and Nutritional 
Examination Surveys (NHANES) reported that the prevalence of CKD increased 
from 10% in 1988-1994 to 13.1% in 1999-2004 (Coresh et al., 2007b).  
 Studies from Australia, and Asia, also, confirm the high prevalence of CKD. 
The prevalence of CKD in Australia was 11.2 percent (Chadban et al., 2003). In 
Asia, the prevalence of CKD ranged from 9.07% to 17.8% (Figure 1.1). The 
prevalence of CKD, in Malaysia was 9.07 percent (Hooi et al., 2013); in China was 
10.8 percent  (Zhang et al., 2012); in Taiwan was 11.9 percent (Delanaye et al., 
2008); in Japan was 12.1 percent (Imai et al., 2009); in Singapore was 12.8 percent 
(Sabanayagam et al., 2010); in Korea was 13.7 percent (Kim et al., 2009); and in 
Thailand was 17.8 percent (Ingsathit et al., 2009). 
                       (2011)        (2010)       (2006)       (2005)        (2007)       (2006)         (2008)
 Figure 1.1.  Prevalence of CKD in Asia
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 However, there are scarce data on the epidemiology of CKD in the Middle 
East, particularly among the Arab countries, and most of the available data is about 
end stage renal disease (ESRD). Due to the absence of national renal registries in 
these countries data that do exist are based on small studies, and because of their 
sample size and design considerations data from these studies have limited 
generalizability  (Table 1.1). Furthermore, the epidemiology of ESRD itself in this 
region is also underreported (Farag et al., 2012, Hassanien et al., 2012). 
Table 1.1. Available data on the epidemiology of CKD and ESRD in the Arab countries
Country Incidence of 
CKD, pmp
Prevalence of 
CKD, pmp
Incidence of 
ESRD, pmp
Prevalence of 
ESRD, pmp
Egypt − − 74 375
Jordan − − 111 312
Kuwait 366 − 78 81
Lebanon − − - 243
Oman − − 100 -
Saudi Arabia − − 136 434
Qatar − − 122 480
UAE − − 74 -
Abbreviations: CKD, chronic kidney disease; ESRD, end stage renal disease; UAE, United 
Arab Emirates; pmp, per million population. (Abboud, 2006, Farag et al., 2012)
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 Diabetes mellitus, hypertension and obesity  are the key risk factors for CKD 
(Coresh et al., 2007b, Haroun et al., 2003). Noticeably, some of these countries such 
as United Arab Emirates (UAE), Saudi Arabia, Bahrain, and Kuwait, have been 
identified by  World Health Organization (WHO) as having ‘very high prevalence of 
diabetes’ (10.2-17.9% range) [Table 1.2]. Extrapolations based on the epidemiology 
of these factors may provide some insight into the epidemiology of CKD. In 2008, 
according to the WHO, the UAE, had an estimated prevalence of diabetes mellitus of 
10.2%, hypertension of 27.5%, and obesity of 32.7% in its adult population. Diabetes 
mellitus was the main cause of ESRD among 23.3% of individuals (Farag et al., 
2012). 
Table 1.2. WHO estimated prevalence (%) of metabolic risk factors in 2008
Country Prevalence of 
diabetes mellitus,%
Prevalence of 
hypertension,%
Prevalence of 
obesity,%
Total 
population
Bahrain 11.0 37.1 32.9 1,261,835
Kuwait 11.9 29.1 42.0 2,736,732
Saudi Arabia 17.9 33.1 33.0 27,448,086
UAE 10.2 27.5 32.7 7,511,690
Abbreviations: UAE, United Arab Emirates. 
4
1.2 Chronic Kidney Disease in the United Arab Emirates 
 Chronic kidney disease is an epidemic in the UAE, and with an increasing 
diabetes and hypertension burden, and growing elderly population CKD is expected 
to increase further. Currently, there is no national or regional renal registry, but 
developing strategies for prevention and management of CKD by the Health 
Ministry of UAE has been a priority, although there is a tremendous challenge ahead 
(Awwad, 2010). 
  May 2009, the Health Ministry of UAE, as part of their commitment to raise 
awareness regarding CKD prevention, organised a public health screening campaign 
which aimed to identify hypertension and diabetes mellitus in the population of Abu 
Dhabi, the capital of UAE. Data collection was performed by a team of nephrology 
staff who screened people for diabetes mellitus and hypertension at selected places 
like shopping centers. Screening was performed over 6 hours period daily. In that 
campaign, more than 3000 people were screened. The detection of either 
hypertension, or diabetes mellitus or both was done by measuring blood glucose 
levels and by  self report. Results revealed that  8% had high blood glucose levels; 
11% were taking antihypertensive medications; 3% were classified as overweight; 
and 0.8% reported family history  of CKD. The screening campaign helped target key 
risk factors for CKD and strengthened the kidney care measures by improving early 
detection and prevention of CKD progression among the population. The results of 
the screening campaign were published in the local press (Awwad, 2010). 
5
1.3 Nephrology Care in Dubai Hospital
The renal unit of the Dubai Hospital, a 625-bed general medical/surgical 
hospital in Dubai, the United Arab Emirates, provides a full range of services for 
adult patients with renal diseases, including the diagnosis and management of acute 
kidney  failure, CKD and nephritic/nephrotic syndrome. The unit cares for renal 
transplant patients starting from as early as 10 days after the transplant, provides 
regular dialysis therapy as haemodialysis or peritoneal dialysis, and provides extra-
corporeal blood purification to patients with intoxication or autoimmune diseases 
(Dubai Health Authority). 
Laboratory tests are usually  aimed at urea, creatinine, electrolytes, and 
urinalysis, which are frequently the key tests when searching for a diagnosis. More 
specialised tests can be ordered to discover or link certain systemic diseases to 
kidney  failure such as hepatitis B or hepatitis C, lupus serologies, paraproteinemias 
(amyloidosis or multiple myeloma) or various other systemic diseases that lead to 
kidney  failure. Other tests often performed by nephrologists are, renal biopsy to 
obtain a tissue diagnosis of a disorder when the exact nature or stage remains 
uncertain; Ultrasound scanning of the urinary tract and occasional examinations of 
the renal blood vessels; CT scanning when mass lesions are suspected (Dubai Health 
Authority).
 
6
1.4 Pharmaceutical Services in Dubai Hospital
 In western countries, the hospital pharmacist has changed its traditional role 
of dispensing and supply  of medication to a more patient-centered pharmaceutical 
care activity (Leufkens et al., 1997). However, this role is not fully applicable to 
hospital pharmacists in UAE. The main activities for hospital pharmacists in UAE 
are preparing and dispensing of medications (Dameh, 2009). For example in Dubai 
Hospital, the pharmacy department provides comprehensive pharmacy services to all 
units of the hospital, including all ambulatory  care clinics, where patients are treated 
with medications. However, pharmacist services are mainly restricted to purchasing, 
stocking and dispensing of the medication products and limited time, if any, is spent 
on assessment of patient needs for pharmaceutical care. 
 Pharmacy education in UAE is based on a product-oriented approval with a 
focus on basic pharmaceutical sciences. This is in contrast with western countries, 
where pharmacy education focuses on pharmaceutical sciences, but there is also an 
emphasis on patient-centered pharmaceutical care aspects. Similarly, in other Middle 
Eastern countries, the changing role of pharmacists in the health care system is 
impacting on hospital pharmacy practice and education, and changes are being 
introduced. For example, during this few years some pharmacy schools in UAE have 
opened a postgraduate clinical pharmacy program. 
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1.5 Pharmacovigilance in the Middle East
 According to World Health Organization-Uppsala Monitoring Centre, 
pharmacovigilance is “the science and activities relating to the detection, assessment, 
understanding and prevention of adverse effects or any drug-related 
problem” (WHO-UMC). While most studies on the drug safety  are conducted in 
western countries, few data are available from the Middle East (Olsson et al., 2010). 
Drug safety  data from developed countries cannot be extrapolated to that of 
developing countries, since the incidence, nature and severity  of adverse drug 
reactions may differ because of different ethnic and genetic backgrounds (Eliasson, 
2006). 
 In a meta-analysis study, McDowell and coauthors (2006) investigated the 
adverse reactions to cardiovascular drugs for different ethnic groups. The authors 
demonstrated that compared to Caucasian patients, having African ethnicity 
conferred a three-fold risk of angioedema from ACEI (angiotensin-converting 
enzyme inhibitor), and higher risk of intracranial haemorrhage from the thrombolytic 
therapy. In their study, the authors reported that African and East Asian patients had a 
higher risk of cough when using ACEIs (McDowell et al., 2006). In addition, other 
influences such as environmental factors, alcohol, smoking, and diet might alter the 
risk of adverse drug reactions in a given population (Pirmohamed and Park, 2001).
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 More recently, the status of pharmacovigilance in the Middle East was 
surveyed using the translated Uppsala Monitoring Centre Assessment of Country 
Pharmacovigilance Situation questionnaire. The author indicated that out of eleven 
participating countries, six countries had an official pharmacovigilance program 
(Egypt, Iraq, Jordan, Oman, Kingdom of Saudi Arabia and the United Arab 
Emirates), while five (Bahrain, Kuwait, Palestine, Qatar and Yemen) reported no 
drug safety related program or centre (Wilbur, 2013).
 The program of medication safety has been recently  introduced in the UAE, 
hence scarce data on pharmacovigilance and ADRs are available from this country. 
In 2008, the UAE government launched the National Pharmacovigilance Centre 
(NPC), where all suspected ADRs and medication errors must be reported in an 
official form (Wilbur, 2013). These forms will then be used to issue safety warnings, 
provide professional education and training, conduct drug regulatory  activities, and 
develop national drug therapeutic guidelines (Wilbur, 2013). 
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1.6 Problem Statement 
 In Dubai, clinical pharmacists spend limited time on clinical services. 
Barriers to the implementation of clinical pharmacy services have been the lack of 
specific clinical training for pharmacists, the limited pharmacy personnel, and the 
fear of poor acceptance from physicians (Dameh, 2009). 
 An important step towards implementing clinical pharmacy  services is to 
target patients who are at high risk for adverse reactions to drugs, because they are 
more likely to benefit. Chronic kidney disease patients are among these, because of 
multiple comorbidities, multiple medication use (Manley et al., 2003), and altered 
pharmacokinetics and pharmacodynamics parameters (Verbeeck and Musuamba, 
2009). 
 Moreover, Patients with CKD display a wide range of abnormalities in the 
homeostatic pathway that may  account for their increased risk for both thrombotic 
events and bleeding (Jalal et al., 2010). The early stages of CKD are mainly 
associated with the prothrombotic tendency (Jalal et al., 2010), whereas in its more 
advanced stages, beside the procoagulant state, platelets can become dysfunctional 
due to uremic-related toxin exposure leading to an increased bleeding tendency  (Jalal 
et al., 2010, Boccardo et al., 2004). The increased risk of thromboembolic diseases 
among CKD patients commonly requires anticoagulation therapy (Dager and Kiser, 
2010). Therefore, this thesis reports the results of the studies performed by a clinical 
pharmacist providing pharmaceutical care on the renal unit of a Dubai Hospital. 
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1.7 General Objectives
 The overall aim of this thesis is to evaluate adverse drug reaction (ADR) 
among hospitalised patients with moderate to severe CKD.
1.7.1 Specific Objectives
 The specific aims of this thesis are as the following:
(1) To determine the incidence and patterns of ADR among hospitalised patients with 
CKD stages 3 to 5.
(2) To assess the type, causality, severity and preventability of each identified ADR.
(3) To identify which drug category causes the most adverse reactions.
(4) To develop an ADR risk assessment score by using routinely obtained baseline 
data from hospitalised patients with CKD stages 3 to 5.
(5) To explore the relationship between anticoagulants use and (a) major bleeding 
events, (b) in-hospital mortality, (c) length of hospital stay, and (d) readmission at 
30 days. 
(6) To study the association among subgroup of patients with anticoagulants use and 
the occurrence of major bleeding events.
(7) To compare the risk of major bleeding associated with the use of UFH versus 
enoxaparin.
(8) To determine the relationship between statin use and risk of anticoagulant-related 
bleeding events.
(9) To examine the association among subgroup of patients with statin use and the 
occurrence of major bleeding events.
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1.8 Framework of Thesis 
 Figure 1.2. outlines the different steps of the thesis work. During the first 
three steps (Chapter 2), ADR was identified among hospitalised patients with CKD 
stages 3 to 5 (estimated glomerular filtration rate, 10–59 ml/min/1.73 m2) who were 
admitted between January 1, 2012, and December 31, 2012, to the renal unit of 
Dubai Hospital. Later, the identified ADRs was assessed for their causality, type, 
severity and preventability. Medication most commonly related to causing ADRs was 
then identified. In the fourth step  (Chapter 3), factors associated with ADRs were 
identified by  using demographic, clinical and laboratory variables of patients with 
CKD stages 3 to 5. An ADR risk score was developed by  constructing a series of 
logistic regression models. The overall model performance for sequential models was 
evaluated using Akaike Information Criterion for goodness of fit. Odd ratios for the 
variables retained in the best model were used to compute the risk scores. During the 
last three steps (Chapter 4), the incidence of adverse outcomes of anticoagulants (in-
hospital mortality, the occurrence of major bleeding, length of hospital stay, and 
readmission at 30 days) in hospitalised patients with CKD was determined. Later, the 
risk of major bleeding events in the use of unfractionated heparin versus adjusted 
therapeutic doses of enoxaparin was compared. Finally, the association of statin use 
with reduced risk of anticoagulant-related bleeding events was studied. Propensity 
score methodology was applied in the last three steps of the thesis; that helped design 
observational studies in a way that is comparable to the way  randomised studies are 
designed.
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Figure 1.2. Framework of thesis
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Step 1. ADR identification (Incidence) 
' ( 
Assessment of the type, causality, severity and 
Step 2. preventability of each identified ADR. 
'if 
Step 3. Identification of medication most commonly implicated in causing the ADRs 
Step 4. Development of an ADR risk assessment score "" ~
Step 5. 
Explore the relationship between anticoagulant use and adverse outcomes ~ ( Major bleeding events, in-hospital mortality, length of hospital stay, and 
readmission at 30 days) 
,,. 
Step 6. 
Comparison of the rates of major bleeding events between 
unfractionated heparin and enoxaparin 
,If 
Step 7. Determine the relationship between statin use and anticoagulant-
related bleeding events 
Abbreviations: ADR, adverse drug reaction. 
CHAPTER 2
ADVERSE DRUG REACTIONS AMONG HOSPITALISED 
PATIENTS WITH MODERATE TO SEVERE CHRONIC 
KIDNEY DISEASE
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2.1 INTRODUCTION 
2.1.1 Terminology of Drug Safety
 There is a large diversity of terms in medical publications for the unwanted 
effects that follow the use of drugs…more than a century ago it  was known as ‘the 
side effects of the drug’ - translated from Louis Lewin, Die Nebenwirkungen der 
Arzneimittel (1881). 
 The term ‘unwanted effect’ is an alternate for ‘adverse effect’; and, the terms 
‘adverse effect’ and ‘adverse reaction’ refer to the same situation, but an adverse 
effect is noticed from the point of the drug, whereas an adverse reaction is noticed 
from the point of the patient. The drug causes an ‘effect’, whereas the patient has a 
‘reaction’. However, the term ‘adverse drug effect (or reaction)’ must be 
differentiated from the term ‘adverse event (or experience)’. An adverse drug 
reaction is an undesirable outcome that can be referred, with some degree of 
causality, to an effect of a drug, whereas an adverse event is an adverse outcome that 
happens while a patient is receiving a drug or at subsequent time but that may or may 
not be referred to an effect of a drug. All adverse drug reaction are adverse events, 
but not all adverse events are adverse drug reaction. This differentiation is important 
in the clinical field, in which not all adverse events are necessarily drug induced 
(Aronson and Ferner, 2005). 
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! This can be further explained in Figure 2.1, a Venn diagram that shows the 
relation between adverse events, adverse drug reactions, and medication errors. For 
example, adverse drug event, as defined by Bates and colleague (1995), is “an injury 
resulting from medical intervention related to a drug”, would involve adverse drug 
reactions, whether caused by medication errors or not, and harm caused by 
medication errors that are not adverse drug reactions (i.e. the areas marked 2, 3 and 4 
in Figure 2.1).
Figure 2.1. A Venn diagram representing the relation between adverse events, 
adverse drug reactions, and medication errors. Figure adapted from (Aronson and 
Ferner, 2005)
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2.1.2 Adverse Drug Reactions
2.1.2.1 Definition 
! Almost thirty years ago an adverse drug reaction (ADR) has been defined by 
the World Health Organization (1975) as: “Any  response to a drug which is noxious 
and unintended, and which occurs at doses normally used in man for prophylaxis, 
diagnosis, or therapy of disease, or for modification of physiological functions.” 
This definition has been commonly used in ADR studies but has been criticised in 
the way that ADR can occur at doses other than those described in the definition, for 
example after a test dose (Aronson and Ferner, 2005). Furthermore, the use of the 
word noxious excludes ADR that may be minor, and thus may undermine the current 
ADR surveillance systems (Edwards and Aronson, 2000, Laurence and Carpenter, 
1998). 
 Alternatively, Edwards and Aronson defined an ADR as: “An appreciably 
harmful or unpleasant reaction, resulting from the use of a medicinal product, which 
predicts hazards from future administration and warrants prevention or specific 
treatment, or alteration of the dosage regimen, or withdrawal of the 
product” (Edwards and Aronson, 2000). This definition excludes ADRs that require 
no intervention and has been used more frequently  in ADR studies (Davies et al., 
2009, Pirmohamed et al., 2004). In this thesis the definition developed by Edwards 
and Aronson was used to identify an ADR.
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2.1.2.2 Types of ADRs 
 Based on a system developed by Rawlin and Thompson, ADRs can be 
classified into two types; type A and B. Type A are those reactions directly related to 
the pharmacological effect of a drug, so-called augmented adverse reactions, and, 
type B are reactions caused by a hypersensitive response of the body to the presence 
of a drug, so-called bizarre adverse reactions. Characteristic for type A adverse 
reactions is common occurrence (>1%), a dose effect relationship and predictability. 
An example of a type A adverse reaction is hypoglycemia caused by antidiabetic 
medications. Characteristics of type B adverse reactions are the rare occurrence 
(<1%), acute in nature and with unexpected onset and severity.  An example of a type 
B adverse drug reaction is the increased destruction of peripheral blood cells caused 
by the immune system involving drug-related antibodies (Rawlins and Thompson, 
1991). 
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2.1.2.3 Causality Assessment of ADRs
 It is essential to detect ADRs and to establish a causal relationship  between 
drugs and their adverse reaction. Many  causality assessment methods have been 
proposed to assess the relationship  between a causative drug and an adverse reaction 
in a given patient. These methods fall into three broad groups: expert judgement, 
comprehensive algorithms and probabilistic methods or Bayesian approaches 
(Agbabiaka et al., 2008). 
 Expert judgements are individual assessments that rely on an expert opinion 
in the area using no standardised tool to achieve a conclusion regarding drug-related 
causality  (Arimone et al., 2005, Wiholm, 1984). Algorithms are sets of questions 
with associated scores for computing the likelihood of a causality (Naranjo et al., 
1981a, Venulet et al., 1986, WHO-UMC). Probabilistic methods or Bayesian 
approaches make use of specific information in an ADR case to transform the prior 
estimate of probability into a posterior estimate of probability  of drug causality 
relationship. The prior probability  is computed from epidemiological information 
and the posterior probability combines the epidemiological information with the 
clinical evidence in the ADR case to reach decision regarding the estimate of 
causation (Lane, 1986, Lane et al., 1987). 
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 The Bayesian concepts have been successfully used in detection of rare and 
severe ADR cases, for example in haematologic dyscrasia associated with ticlopidine 
therapy (Paradiso-Hardy  et al., 2000), and Guillain-Barre Syndrome due to 
zimeldine therapy (Naranjo et al., 1990). However, the complexity  of the Bayesian 
approaches makes it  unsuitable for routine clinical use. In addition when this 
approach was compared with the Naranjo algorithm it was found that assessments of 
ADR using both methods were significantly correlated (r = 0.45, P<0.0001) (Lanctôt 
and Naranjo, 1995)
 It is clinically important that all suspected ADRs should be objectively  
assessed and presented using a suitable causality  assessment tool. There is still no 
method widely accepted for the causality assessment of ADRs (Agbabiaka et al., 
2008), however, among the above mentioned methods, the Naranjo algorithm 
(Naranjo et al., 1981a) is the most frequently used for causality assessment of ADRs 
in the literature and clinical practice as it offers a simple methodology. The algorithm 
classifies ADRs into definite (score, 9-12 points), probable (score, 5-8 points), 
possible (score, 1-4 points), or doubtful (score, 0 point) (Table 2.1).
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2.1. Adverse drug reaction causality assessmenta, Naranjo algorithmb
Question Yes No Do Not 
Know 
Are there previous conclusive reports on this reaction? +1 0 0
Did the adverse event appear after the suspected drug was 
administrated?
+2 -1 0
Did the adverse reaction improve when the drug was 
discontinued or a specific antagonist was administrated? 
+1 0 0
Did the adverse reaction reappear when the drug was 
readministered?
+2 -1 0
Are there alternative causes (other than the drug) that could 
solely have caused the reaction?
-1 +2 0
Did the reaction reappear when a placebo was given? -1 +1 0
Was the drug detected in the blood (or other fluids) in a 
concentration known to be toxic?
+1 0 0
Was the reaction more severe when the dose was increased, 
or less severe when the dose was decreased?
+1 0 0
Did the patient have a similar reaction to the same or similar 
drugs in any previous exposure?
+1 0 0
Was the adverse event confirmed by objective evidence? +1 0 0
aThe total number of points calculated from this table define the category an adverse drug 
reaction belongs to. The categories are defined as follows: definite (score, 9-12 points), 
probable (score, 5-8 points), possible (score, 1- 4 points), or doubtful (score, ≤0 point).
b(Naranjo et al., 1981a)
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2.1.2.4 Severity Assessment of ADRs
 The term severity  is often used to explain the intensity of a medical event, as 
in grading ‘mild’, ‘moderate’ and ‘severe’. Severity assessment categorises the ADRs 
as mild, moderate, or severe based on the steps taken for the management of the 
ADRs. According to WHO criteria; a serious ADR is classified as one which is fatal, 
life threatening, requires or prolongs hospitalisation, and/or results in significant 
persistent disability or incapacity (WHO-UMC).
 In 1963, in a study of evaluating the hazards of hospitalization, Schimmel 
referred to any untoward events or complication of therapy as ‘episodes’. In the 
study, an episode was classified as minor, if it was short and subsided without 
specific therapy; as moderate, if it required significant therapy, or if it  prolonged 
hospital stay by a day or more; and as major if it was life-threatening or fatal. 
 In 1992, Hatwig and Siegel developed a simple scale for assessing the 
severity of ADRs. The scale was originally adapted from a severity-indexed scale 
already being used to review significant medication-administration errors (Hartwig et 
al., 1991) and the concepts are similar to those of Schimmel (1963), with length of 
stay, therapy required, and prognosis being the main focus of severity  assessment. 
The scale classifies ADRs into seven levels according to their severity. Levels 1&2 
fall under mild category whereas levels 3 & 4 fall under moderate and levels 5, 6 & 7 
fall under severe category (Table 2.2).
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Table 2.2. Adverse drug reaction severity assessment, Hartwig and Siegel scalea
Level Description Scale
1 An ADR occurs but requires no change in treatment with the 
suspected drug.
Mild
2 The ADR requires that the suspected drug be withheld, 
discontinued, or otherwise changed. No antidote or other 
treatment is required, and there is no increase in length of stay.
Mild
3 The ADR requires that the suspected drug be withheld, 
discontinued, or otherwise changed, and/or an antidote or other 
treatment is required, and there is no increase in length of stay.
Moderate 
4 a) Any level 3 ADR that increases length of stay by at least one 
day, or (b) The ADR is the reason for admission.
Moderate 
5 Any level 4 ADR that requires intensive medical care. Severe
6 Did the reaction reappear when a placebo was given? Severe
7a The adverse reaction causes permanent harm to the patient. Severe
7b The adverse reaction either directly or indirectly leads to the 
death of the patient.
Severe
Abbreviations: ADR, adverse drug reaction. 
a(Davies et al., 2009, Hartwig et al., 1992)
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2.1.2.5 Preventability Assessment of ADRs
 At a first glimpse, one can simply classify which ADRs are preventable by 
their type and conclude that a type A reaction is predictable and hence, is preventable 
whereas a Type B reaction is not predictable and is therefore, not preventable 
(Rawlins and Thompson, 1991). However, in clinical practice type A ADRs might 
not be always preventable, sometime there are few clinical alternatives but to use the 
drug in the patient. Type B reactions can also be prevented if previous allergy to an 
ADR is noticed before administration. This is emphasised on the importance of using 
a structured method for assessing the preventability of ADRs.
 In 1990, Hallas and colleagues developed criteria or definitions to assess 
preventability of an ADR. The criteria are shown in Table 2.3.
Table 2.3. Adverse drug reaction preventability assessment, Hallas et al. criteriaa
Criteria
The ADR was due to a drug treatment procedure inconsistent 
with current knowledge of good medical practice
Definitely preventable
The ADR could have been avoided by an effort exceeding 
the obligatory demand of current knowledge of good 
medical practice
Possibly preventable
The ADR could not have been avoided by any reasonable
means
Non-preventable
Abbreviations: ADR, adverse drug reaction. 
a(Hallas et al., 1990)
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